The safety comparison results from this studies identifies that, CLC insulin delivery was associated with fewer AEs, especially hypoglycemic and hyperglycemic-related events during day and night, than SAP which deems CLC to be an ideal treatment of choice for adolescents with type 1 diabetes. The gene discussed is INS; the disease is type 1 diabetes mellitus.